论文部分内容阅读
糖尿病肾病是糖尿病患者的主要微血管并发症之一，也是目前慢性肾脏疾病和终末期肾病的主要全球性病因。白蛋白尿和估计肾小球滤过率是目前临床上诊断早期糖尿病肾病较为认可的指标，然而其灵敏度及特异度均不佳。因此，寻找新的生物标志物来反映更早期和更精确的在临床静默期内的潜在的糖尿病肾病变显得尤为关键。“,”Diabetic nephropathy (DN) is one of the major microvascular complications in diabetic patients, and it is also the main global cause of chronic kidney disease(CKD) and end-stage renal disease(ESRD). Albuminuria and estimated glomerular filtration rate (eGFR) are currently recognized as clinically diagnosed early DN, but their sensitivity and specificity are poor. Therefore, it is very important to find new biomarkers to reflect the potential diabetic nephropathy in the clinical silent period.